Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $350.00

Posted by Brian Himes on Nov 6th, 2026

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price objective hoisted by HC Wainwright from $280.00 to $350.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s target price suggests a potential upside of 97.02% from the stock’s previous close.

Several other analysts have also issued reports on the company. UBS Group upped their target price on Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, August 28th. Brookline Capital Markets began coverage on Revolution Medicines in a research note on Monday, September 28th. They issued a “buy” rating and a $318.00 price target for the company. Stifel Nicolaus boosted their price target on Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Morgan Stanley initiated coverage on Revolution Medicines in a research report on Thursday, September 10th. They set an “overweight” rating and a $255.00 price target on the stock. Finally, Wedbush upped their price objective on Revolution Medicines from $201.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.15.

Read Our Latest Analysis on Revolution Medicines

Revolution Medicines Trading Down 11.0%

Shares of NASDAQ:RVMD opened at $177.65 on Friday. The company’s 50-day moving average price is $197.46 and its two-hundred day moving average price is $157.18. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. Revolution Medicines has a one year low of $58.91 and a one year high of $224.31. The stock has a market capitalization of $38.08 billion, a PE ratio of -19.50 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to analyst estimates of $25.58 million. During the same quarter in the prior year, the company earned ($1.61) earnings per share. On average, equities analysts forecast that Revolution Medicines will post -8.94 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Lorence Kim sold 56,000 shares of the business’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $203.24, for a total transaction of $11,381,440.00. Following the transaction, the director directly owned 17,090 shares in the company, valued at $3,473,371.60. The trade was a 76.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Elizabeth Anderson sold 10,143 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the sale, the director directly owned 4,333 shares in the company, valued at approximately $836,442.32. The trade was a 70.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 290,991 shares of company stock worth $59,422,765. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of institutional investors have recently bought and sold shares of RVMD. Alphabet Inc. bought a new position in shares of Revolution Medicines during the 2nd quarter worth approximately $551,843,000. Assenagon Asset Management S.A. raised its stake in Revolution Medicines by 987.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after acquiring an additional 1,980,699 shares during the period. ABS Investment Management LLC bought a new stake in Revolution Medicines in the 2nd quarter valued at $337,104,000. Bank of America Corp DE bought a new stake in Revolution Medicines in the 2nd quarter valued at $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Revolution Medicines by 82.3% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock valued at $170,862,000 after purchasing an additional 411,740 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

Positive Sentiment: Third-quarter revenue reached $197.6 million, far above the $25.58 million consensus estimate. Nearly all of it came from RASONQUE during its first five weeks on the U.S. market; reports cited treatment of more than 5,000 patients. The quarterly loss of $1.90 per share was also narrower than the expected $2.35, though wider than a year earlier. Zacks report on Q3 sales and RASONQUE uptake
Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for daraxonrasib (RASONQUE) in the EU, adding a potential international growth opportunity. Company Q3 results and corporate update
Positive Sentiment: Several firms raised their targets and maintained bullish ratings. RBC increased its target to $321 from $260 with an Outperform rating; TD Cowen raised its target to $270, and Guggenheim to $298, both with Buy ratings. RBC price-target report
Negative Sentiment: Brookline Capital Markets lowered its FY2029 and FY2030 EPS forecasts to $8.49 and $17.41, respectively, from $8.94 and $18.15. It nevertheless kept its Buy rating and $318 price target.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.